Sickle cell anemia. Pathophysiology and treatment.
Current concepts of the pathophysiology of the sickling process are reviewed. New approaches to treatment - including induced hyponatremia, membrane-active antisickling agents, and gene manipulation - are described.
D000755:Anemia, Sickle Cell / Q000097:blood / Q000150:complications / Q000628:therapy*; D000986:Antisickling Agents / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D001381:Azepines / Q000627:therapeutic use; D001803:Blood Transfusion; D002561:Cerebrovascular Disorders / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010640:Phenothiazines / Q000627:therapeutic use; D011008:Pneumococcal Infections / Q000517:prevention & control; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000628:therapy; D011317:Priapism / Q000209:etiology; D014508:Urea / Q000627:therapeutic use; D014611:Vaccination
D000986:Antisickling Agents; D001381:Azepines; D010640:Phenothiazines; C006955:cetiedil; D014508:Urea; D005492:Folic Acid; D001374:Azacitidine